Ondine Biomedical Inc
Research Ondine Biomedical Inc (OBI) on Bullrun: market cap GBX 7.01B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOBI
- ExchangeLSE
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 7.01B
- Financial periodFY2025
- RevenueCAD 2.65M
- Revenue growth29.1%
- Net income-CAD 29.52M
- Free cash flow-CAD 23.96M
- Gross margin60.9%
Valuation Snapshot
latest market cap is GBX 7.01B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 2.65M | -CAD 29.52M | -CAD 23.96M | 60.9% | n/a | CAD 10.57M | CAD 413.00K | CAD 3.49M |
| FY2024 | CAD 2.05M | -CAD 19.10M | -CAD 15.50M | 64.5% | -0.07 | CAD 9.77M | CAD 168.00K | CAD 6.88M |
| FY2023 | CAD 1.20M | -CAD 14.41M | -CAD 13.83M | 58.4% | -0.07 | CAD 2.98M | CAD 541.00K | CAD 2.09M |
| FY2022 | CAD 638.00K | -CAD 19.37M | -CAD 16.66M | 45.0% | -0.1 | CAD 13.13M | CAD 896.00K | CAD 11.64M |
| FY2021 | CAD 2.57M | -CAD 50.09M | -CAD 12.62M | 48.8% | -0.63 | CAD 30.37M | CAD 739.00K | CAD 29.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | GBX 7.01B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ondine Biomedical Inc's market cap?
Ondine Biomedical Inc's market capitalization is GBX 7.01B.
What does Ondine Biomedical Inc do?
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc.